What is the difference between Amycretin and Semaglutide?

Amycretin is classified as: Unimolecular GLP-1 and amylin receptor co-agonist. Semaglutide is classified as: Glucagon-like peptide-1 (GLP-1) receptor agonist. Amycretin is investigational and is not an approved medicine. Semaglutide is approved for one or more medical uses in at least one major jurisdiction.

Is Amycretin or Semaglutide approved?

Amycretin is investigational and is not an approved medicine. Semaglutide is approved for one or more medical uses in at least one major jurisdiction. Regulatory status by region is set out in the table above.

How much clinical trial evidence is tracked for Amycretin and Semaglutide?

Peptide Science Daily tracks 21 registered clinical trials for Amycretin (evidence grade C) and 500 for Semaglutide (evidence grade A).

Compound comparison

Amycretin vs Semaglutide

This page sets Amycretin and Semaglutide side by side using the data recorded on Peptide Science Daily: drug class, mechanism of action, regulatory status by region, the evidence grade assigned here, and the number of clinical trials tracked. It is a neutral, factual comparison and does not rank either compound or recommend one over the other.

Side-by-side comparison

Class: Amycretin
Unimolecular GLP-1 and amylin receptor co-agonist
Semaglutide
Glucagon-like peptide-1 (GLP-1) receptor agonist
Mechanism: Amycretin
In plain terms, amycretin is one molecule that acts on two appetite-regulating targets at once: the GLP-1 receptor, the target of drugs such as semaglutide, and the amylin receptor.
Semaglutide
In plain terms, semaglutide copies a natural gut hormone that signals fullness and helps control blood sugar.
United States (FDA): Amycretin
Not approved. Investigational only; in early-to-mid phase clinical development for obesity and not authorized for any indication.
Semaglutide
Approved. Ozempic for type 2 diabetes (2017, cardiovascular risk reduction added 2020); Rybelsus oral for type 2 diabetes (2019); Wegovy for chronic weight management (2021) and cardiovascular risk reduction (2024); oral Wegovy for weight management approved in 2025.
European Union (EMA): Amycretin
Not authorized. Investigational; no EU marketing authorisation.
Semaglutide
Authorized - Ozempic and Rybelsus for type 2 diabetes and Wegovy for weight management.
Australia (TGA): Amycretin
Not registered on the Australian Register of Therapeutic Goods (ARTG). Investigational; not approved in Australia.
Semaglutide
Registered on the ARTG - Ozempic for type 2 diabetes and Wegovy for weight management, available on prescription.
WADA: Amycretin
Not listed on the WADA Prohibited List and not in the 2026 Monitoring Program (which names only markers of semaglutide and tirzepatide).
Semaglutide
Not prohibited. On the WADA Monitoring Program (introduced 2024, continued into 2026); it is tracked but not a banned substance.
Evidence grade: Amycretin
C
Semaglutide
A
Tracked clinical trials: Amycretin
21
Semaglutide
500
Full profile: Amycretin
Amycretin profile
Semaglutide
Semaglutide profile

Comparison of Amycretin and Semaglutide by class, mechanism, regulatory status by region, evidence grade, and number of tracked clinical trials.
Attribute	Amycretin	Semaglutide
Class	Unimolecular GLP-1 and amylin receptor co-agonist	Glucagon-like peptide-1 (GLP-1) receptor agonist
Mechanism	In plain terms, amycretin is one molecule that acts on two appetite-regulating targets at once: the GLP-1 receptor, the target of drugs such as semaglutide, and the amylin receptor.	In plain terms, semaglutide copies a natural gut hormone that signals fullness and helps control blood sugar.
United States (FDA)	Not approved. Investigational only; in early-to-mid phase clinical development for obesity and not authorized for any indication.	Approved. Ozempic for type 2 diabetes (2017, cardiovascular risk reduction added 2020); Rybelsus oral for type 2 diabetes (2019); Wegovy for chronic weight management (2021) and cardiovascular risk reduction (2024); oral Wegovy for weight management approved in 2025.
European Union (EMA)	Not authorized. Investigational; no EU marketing authorisation.	Authorized - Ozempic and Rybelsus for type 2 diabetes and Wegovy for weight management.
Australia (TGA)	Not registered on the Australian Register of Therapeutic Goods (ARTG). Investigational; not approved in Australia.	Registered on the ARTG - Ozempic for type 2 diabetes and Wegovy for weight management, available on prescription.
WADA	Not listed on the WADA Prohibited List and not in the 2026 Monitoring Program (which names only markers of semaglutide and tirzepatide).	Not prohibited. On the WADA Monitoring Program (introduced 2024, continued into 2026); it is tracked but not a banned substance.
Evidence grade	C	A
Tracked clinical trials	21	500
Full profile	Amycretin profile	Semaglutide profile

Common questions

What is the difference between Amycretin and Semaglutide?: Amycretin is classified as: Unimolecular GLP-1 and amylin receptor co-agonist. Semaglutide is classified as: Glucagon-like peptide-1 (GLP-1) receptor agonist. Amycretin is investigational and is not an approved medicine. Semaglutide is approved for one or more medical uses in at least one major jurisdiction.
Is Amycretin or Semaglutide approved?: Amycretin is investigational and is not an approved medicine. Semaglutide is approved for one or more medical uses in at least one major jurisdiction. Regulatory status by region is set out in the table above.
How much clinical trial evidence is tracked for Amycretin and Semaglutide?: Peptide Science Daily tracks 21 registered clinical trials for Amycretin (evidence grade C) and 500 for Semaglutide (evidence grade A).